Add BrightSurf on Google Email

Breakthrough cardiac regeneration research offers hope for the treatment of ischemic heart failure

Researchers have discovered a new way to stimulate cardiomyocyte proliferation, offering promising results in both human cardiac slices and live animals. This innovative approach targets calcium signaling pathways, potentially transforming the treatment landscape for patients suffering from heart failure.

SourceBaylor College of Medicine·Journalnpj Regenerative Medicine·TypeExperimental study·DateMar 7, 2025

Diabetes drug could help cancer patients make better recovery

A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...

SourceUniversity of East Anglia·JournalEuropean Journal of Preventive Cardiology·TypeMeta-analysis·DateMar 5, 2025

Patient-doctor common tongue key to decreasing cardiovascular disease, longer life

A retrospective cohort study from the University of Ottawa and Manitoba found Canadians with hypertension whose preferred language was spoken by their doctor were 36% less likely to have a major adverse cardiovascular event. Patients with language-accessible care had a 28% lower risk of death compared to those without such access.

SourceUniversity of Ottawa·JournalJAMA Network Open·TypeData/statistical analysis·DateFeb 21, 2025

A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes

A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 14, 2025

A simple supplement improves survival in patients with a new type of heart disease

A study published in Nature Cardiovascular Research found that tricaprin improved long-term survival and recovery from heart failure in patients with triglyceride deposit cardiomyovasculopathy. The supplement reversed structural changes and improved heart muscle function, leading to higher survival rates compared to controls.

SourceOsaka University·JournalNature Cardiovascular Research·TypeObservational study·DateFeb 13, 2025

JSCAI article at THT 2025 sets the standard for training pathways in interventional heart failure

The article proposes clear career paths and standardized training pathways in interventional heart failure, aiming to enable specialists to drive innovation and improve outcomes. It highlights the need for a formalized approach to training and career development in this field.

SourceSociety for Cardiovascular Angiography and Interventions·JournalJournal of the Society for Cardiovascular Angiography & Interventions·TypeRandomized controlled/clinical trial·DateFeb 11, 2025

240-year-old drug could save UK National Health Service £100 million a year treating common heart rhythm disorder

A new study from the University of Birmingham found that digoxin is more effective than beta-blockers in reducing adverse events and hospital admissions for older patients with atrial fibrillation. This could lead to significant cost savings for the UK National Health Service, estimated at £102 million per year.

SourceUniversity of Birmingham·JournalHeart·TypeData/statistical analysis·DateJan 31, 2025

Fatty muscles raise the risk of serious heart disease regardless of overall body weight

Research published in the European Heart Journal found that people with high amounts of intermuscular fat are more likely to develop coronary microvascular dysfunction and future serious heart disease. The study's lead author suggests that existing measures of obesity may not be accurate for all individuals, particularly women.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·TypeObservational study·DateJan 19, 2025

Presenting a path forward for future genetically-modified pig heart transplants: lessons learned from second patient

Researchers from the University of Maryland School of Medicine analyzed the second patient to receive a genetically-modified pig organ, identifying key factors contributing to rejection and highlighting areas for improvement. The study provides valuable insights into how to prevent graft failure in future transplants.

SourceUniversity of Maryland School of Medicine·JournalNature Medicine·TypeCase study·DateJan 8, 2025

Human cardiac organoid model reveals antibacterial triclocarban promotes myocardial hypertrophy by interfering with endothelial cell metabolism

Exposure to triclocarban, a common antibacterial agent, promotes myocardial hypertrophy in human cardiac organoids. The study found that TCC interferes with endothelial cell metabolism, leading to nitrosative stress and inflammation. This new mechanism suggests a potential treatment target for myocardial hypertrophy.

SourceScience China Press·JournalScience Bulletin·DateJan 4, 2025

SABCS: Improved survival for advanced breast cancer, using genomics to identify patients with high risk of recurrence, how race/ethnicity influence the risk of heart failure in early-stage breast cancer and more

Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...

Tiny, daily bursts of vigorous incidental physical activity could almost halve cardiovascular risk in middle-aged women

A study found that middle-aged women who engaged in short bursts of vigorous physical activity, such as carrying shopping or power walking, had a significantly lower risk of heart attacks and heart failure. Women who averaged 3.4 minutes of daily activity were 45% less likely to experience a major cardiovascular event.

SourceUniversity of Sydney·JournalBritish Journal of Sports Medicine·TypeObservational study·DateDec 3, 2024

World’s most common heart valve disease linked to insulin resistance in large national study

Researchers found a novel link between aortic stenosis and insulin resistance, with certain biomarkers increasing the risk of the disease. The study's findings suggest that managing metabolic health could be a new approach to reduce the risk of AS and improve cardiovascular health in aging populations.

SourceTaylor & Francis Group·JournalAnnals of Medicine·TypeData/statistical analysis·DateNov 27, 2024

U of M researchers find connection between blood protein and increased heart failure risk

A recent study published in Circulation found a correlation between lower levels of coagulation factor XI and an increased risk of heart failure. The research, conducted on two large community-based cohorts, also linked lower factor XI levels to a greater likelihood of atrial fibrillation and worse heart function.

SourceUniversity of Minnesota Medical School·JournalCirculation·TypeExperimental study·DateNov 21, 2024

Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction

Prescription rates of sodium-glucose cotransporter-2 inhibitors increased substantially within 2 years after publication of clinical trial evidence documenting benefit. The study highlights the need to understand strategies used by higher prescribing centers to increase SGLT2i adoption.

SourceJAMA Network·JournalJAMA Cardiology·DateNov 18, 2024

Anti-obesity drugs, lifestyle interventions show cardiovascular benefits beyond weight loss

Studies published in JACC found that anti-obesity drugs such as tirzepatide and semaglutide improved cardiac structure and function, as well as reduced cardiac risk biomarkers with lifestyle interventions. These findings suggest that these treatments may have a transformative impact on cardiovascular health beyond weight loss.

SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·DateNov 18, 2024